Clinical Trials and Research
Jun 20, 2020
AbstractTransthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally…
Bayer has reported that iodine 124 evuzamitide met both primary endpoints in the Phase III REVEAL study, demonstrating sufficient sensitivity and specificity for…
ardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular…
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic
leukaemia, and data across multiple haematology assets showcase breadth of…
Published: Oct 09, 2023
- FDA Cites Insufficient Evidence of Clinical Meaningfulness -
- No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
- Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR…
Nexcella, Inc., a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced…
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed…
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced…